Mimetas Inc. | Date: 2015-11-03
Scientific, optical measurement and inspection apparatus and instruments for producing, growing and studying biological tissues; laboratory apparatus for the production and culture of cells and tissues, and research into cells, tissues and organs. Research, design and development of microfluidic products for use in scientific research laboratories in the medical, chemical, pharmaceutical and veterinary fields; research, design and development of cells, tissues and organs for use in scientific research laboratories in the medical, pharmaceutical, cosmetic, surgical, dental and veterinary field; development and research into biological tissues and organs models; scientific and industrial research and for health care services. Medical and pharmaceutical services, including services for the diagnosis of disorders of the human body, development of tissue and organ models, development of personalized diagnostic tests, to determine the effects and side effects of drugs and potential drugs; information services relating to pharmaceutical services provided via online computer networks; medical care services in the field of hygiene, beauty; providing information in the field of diagnostics; providing medical information to medical professionals on patients with artificially produced biological tissues and organs from a website; health information, namely, providing information about products and services via global computer networks for health; medical analysis for the diagnosis and treatment of persons.
Agency: Cordis | Branch: H2020 | Program: MSCA-ITN-EID | Phase: MSCA-ITN-2015-EID | Award Amount: 1.06M | Year: 2016
MIMIC is an interdisciplinary European Industrial Doctorate at the interface of cell biology, engineering and drug development. MIMIC aims to develop and improve novel organs on chips technology. This technology combines modern cell biology with microfluidics and chip-based techniques with the goal to mimic organ functionality. There is a high demand by the pharmaceutical industry for more reliable tissue models to test drug toxicity and drug efficiency at early stages of drug development. Early reliable drug testing will have a major impact on drug development costs and human health. Furthermore, ethical considerations urge for the search for alternatives to replace animal tests in drug development and basic research. Organs on chips are a new exciting possibility to closer mimic human organ functionality in vitro than conventional 2D or 3D cell cultures. Organs on chips allow both, the emulation of healthy organs as well as the emulation of specific disease conditions using corresponding engineered or patient derived human cells. Moreover, organs on chips are ideally suited for high-throughput drug screening. The EID-MIMIC will develop novel organs on chips prototypes, and validate their suitability for end-users for high throughput drug screening or basic research. MIMIC will train early stage researchers in cutting edge technologies, like novel chip based technologies e.g. cell micropatterning, soft-lithography and microfluidics technology, as well as state of the art microscopy like super resolution- and confocal spinning disc microscopy and modern genome editing techniques like CRISPR-technology. In addition, MIMIC has developed a 3 year modular curriculum including workshops on creativity and business skills, summer schools, business plan competitions and international conferences with a specific agenda of transferable skill training elements highly relevant for scientific communication, translational research and, in particular, entrepreneurship.
Mimetas Inc. | Entity website
Fluorescent and chemiluminescent:Fluorescent live-dead assaysFluorescent live cell tracker dyesGFP, BFP, RFPChemiluminescent assays (luciferase)Immunohistochemistry, antibody-stains:Antibody detection, multi colour fluorescenceTransport and leakage assays:Transport of fluorescent dyes across epitheliaLeakage of dextran-conjugated dyes through epitheliaMetabolites, (LC)-MSLC-MS metabolite analysis on output medium
Yildirim E.,Leiden University |
Yildirim E.,Cankaya University |
Trietsch S.J.,Leiden University |
Trietsch S.J.,Mimetas Inc. |
And 5 more authors.
Lab on a Chip - Miniaturisation for Chemistry and Biology
A microfluidic passive valving platform is introduced that has full control over the stability of each valve. The concept is based on phaseguides, which are small ridges at the bottom of a channel acting as pinning barriers. It is shown that the angle between the phaseguide and the channel sidewall is a measure of the stability of the phaseguide. The relationship between the phaseguide-wall angle and the stability is characterized numerically, analytically and experimentally. Liquid routing is enabled by using multiple phaseguide with different stability values. This is demonstrated by filling complex chamber matrices. As an ultimate demonstration of control, a 400-chamber network is used as a pixel array. It is the first time that differential stability is demonstrated in the realm of passive valving. It ultimately enables microfluidic devices for massive data generation in a low-cost disposable format. © 2014 the Partner Organisations. Source
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: PHC-03-2015 | Award Amount: 5.10M | Year: 2015
Common mechanisms and pathways in Stroke and Alzheimers disease. It has long been recognized that stroke and (Alzheimers Disease) AD often co-occur and have an overlapping pathogenesis. As such, these two diseases are not considered fellow travelers, but rather partners in crime. This multidisciplinary consortium includes epidemiologists, geneticists, radiologists, neurologists with a longstanding track-record on the etiology of stroke and AD. This project aims to improve our understanding of the co-occurrence of stroke and AD. An essential concept of our proposal is that stroke and AD are sequential diseases that have overlapping pathyphysiological mechanisms in addition to shared risk factors. We will particularly focus on these common mechanisms and disentangle when and how these mechanisms diverge into causing either stroke, or AD, or both. Another important concept is that mechanisms under study will not only include the known pathways of ischemic vasculopathy and CAA, but we will explore and unravel novel mechanisms linking stroke and AD. We will do so by exploiting our vast international network in order to link various big datasets and by incorporating novel analytical strategies with emerging technologies in the field of genomics, metabolomics, and brain MR-imaging.